Supernus PharmaceuticalsSUPN
SUPN
About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Employees: 674
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
323% more call options, than puts
Call options by funds: $994K | Put options by funds: $235K
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
16% more capital invested
Capital invested by funds: $1.86B [Q3] → $2.15B (+$293M) [Q4]
7% more funds holding
Funds holding: 270 [Q3] → 290 (+20) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 94
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.64% less ownership
Funds ownership: 108.34% [Q3] → 107.71% (-0.64%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$36
8%
upside
Avg. target
$36
8%
upside
High target
$36
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Cantor Fitzgerald Kristen Kluska 28% 1-year accuracy 27 / 97 met price target | 8%upside $36 | Neutral Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 22 articles about SUPN published over the past 30 days
Negative
Zacks Investment Research
2 days ago
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highest implied volatility of all equity options today.
Neutral
Accesswire
1 week ago
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Seeking Alpha
1 week ago
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen David Amsellem - Piper Sandler Operator Good afternoon and welcome to Supernus Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
1 week ago
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
1 week ago
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to break-even earnings per share a year ago.
Neutral
GlobeNewsWire
1 week ago
Supernus Announces First Quarter 2025 Financial Results
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.
Neutral
Accesswire
1 week ago
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SUPN
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Charts implemented using Lightweight Charts™